(Q36304804)

13 August 2017

1 reference

title

Atazanavir: a review of its use in the management of HIV infection (English)

1 reference

13 August 2017

1 reference

2

Lesley J Scott

1 reference

13 August 2017

Tracy Swainston Harrison

series ordinal

1

1 reference

13 August 2017

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

65

1 reference

13 August 2017

16

1 reference

13 August 2017

2309-2336

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565160-00010

13 August 2017

0 references

cites work

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

1 reference

12 December 2020

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

1 reference

12 December 2020

Boosted PIs: competition hots up

1 reference

12 December 2020

Predictors of virological response to atazanavir in protease inhibitor-experienced patients

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

1 reference

12 December 2020

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

1 reference

12 December 2020

Reviving protease inhibitors: new data and more options.

1 reference

12 December 2020

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

1 reference

12 December 2020

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

1 reference

12 December 2020

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable

1 reference

12 December 2020

Pharmacologic perspectives for once-daily antiretroviral therapy

1 reference

12 December 2020

Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia

1 reference

12 December 2020

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

12 December 2020

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

12 December 2020

Atazanavir: new option for treatment of HIV infection

1 reference

12 December 2020

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

1 reference

12 December 2020

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

1 reference

12 December 2020

Releasing the true power of protease inhibitors

1 reference

12 December 2020

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

12 December 2020

Lipid abnormalities during ART: it's the drug, not the class.

1 reference

12 December 2020

1 reference

12 December 2020

Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

1 reference

12 December 2020

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

1 reference

12 December 2020

1 reference

12 December 2020

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir

1 reference

12 December 2020

Atazanavir: a novel HIV-1 protease inhibitor

1 reference

12 December 2020

10.2165/00003495-200565160-00010

Identifiers

DOI

1 reference

PubMed ID

16266202

Dimensions Publication ID

13 August 2017

0 references

1 reference

PubMed ID

16266202